: A total of 948 patients met inclusion criteria and 847 had no known EGFR or ALK mutation. In these 847 patients, the median age was 69, 455 (55.0%) were female, 600 (70.8%) were White, and 623 (73.6%) were treated in community oncology practices
Search Results
HSR24-162: Treatment Patterns in Surgically Resected NSCLC Since the Introduction of Immuno-Oncology Agents
Jhanelle E. Gray, Daniel Simmons, Lu Zou, Yahan Zhang, Wale Oyebanji, and Tiernan Mulrooney
Non–Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology
Gregory J. Riely, Douglas E. Wood, David S. Ettinger, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Aakash P. Desai, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aditya Juloori, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Dawn Owen, Dwight H. Owen, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Jonathan Riess, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Lisa Hang
mutation) by one method suggest that a complementary method may be used. Molecular testing for EGFR, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET , and ERBB2 (HER2) alterations is recommended in all patients with advanced or metastatic
Small Cell Lung Cancer in Light/Never Smokers – A Role for Molecular Testing?
Gordon Taylor Moffat, Tao Wang, and Andrew G. Robinson
targeted therapy to driver mutations in EGFR and ALK have revolutionized management with the prolongation of profession-free and overall survivals. Additional targeted therapies include agents targeting MET , RET , ROS1 , KRAS , BRAF , and ERBB2
Incorporation of Crizotinib into the NCCN Guidelines
Gregory J. Riely, Jamie E. Chaft, Marc Ladanyi, and Mark G. Kris
The past 7 years have seen dramatic changes in our understanding of the pathogenesis and treatment of lung cancers. The clearest examples of these advances are erlotinib and gefitinib, the epidermal growth factor receptor (EGFR) tyrosine kinase
Biomarkers with Predictive and Prognostic Function in Non–Small Cell Lung Cancer: Ready for Prime Time?
Charu Aggarwal, Neeta Somaiah, and George R. Simon
growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)/neu kinase domains. 40 – 42 Slebos et al. 43 evaluated the relationship among KRAS activation, tumor characteristics, and survival in patients with NSCLC. Tumors positive
Highlights of the NCCN Oncology Research Program
Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck Principal Investigator: Aarti Bhatia, MD, MPH Condition
Using Cellular Mechanisms to Develop Effective Combinations of Photodynamic Therapy and Targeted Therapies
Tayyaba Hasan
to PDT in prostate, pancreatic, and ovarian cancer cell models is discussed, featuring the roles of both vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in guiding the selection of targeted agents to join PDT in
Genomic Testing in Lung Cancer: Past, Present, and Future
Céline Mascaux, Ming-Sound Tsao, and Fred R. Hirsch
( EGFR ) mutations received 150 mg of erlotinib for 1 year; ERCC1-negative patients received 4 courses of cisplatin/pemetrexed, whereas ERCC1-positive patients underwent follow-up. 4 These recent data are based on a small cohort of patients with a low
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN, and Miranda Hughes
-line therapy with osimertinib for certain patients with metastatic NSCLC and EGFR mutations. However, the 2020 update of the guidelines has expanded the preference stratification categories to include all of the systemic therapy regimens. First
Management of Dermatologic Toxicities
Mario E. Lacouture
made several key points about skin rash produced by different cancer therapies: Most patients taking EGFR inhibitors develop an acneiform rash on the face, scalp, and upper body, often within the first 4 weeks. This is associated with pruritus
